Myriad Genetics (MYGN) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
February 2, 2016 4:05 PM ESTTotal Revenues of $193.3 Million Adjusted Diluted EPS of $0.45 and Diluted EPS of $0.41 Company Maintains Fiscal Year 2016 Revenue Guidance, Raises Fiscal Year 2016 Earnings Guidance and Provides Fiscal Third-Quarter 2016 Financial Guidance
SALT LAKE CITY, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal second-quarter 2016, provided an update on recent business highlights, maintained its fiscal year 2016 revenue guidance, raised its fiscal year 2016 earnings guidance and provided fiscal third-quarter 2016 financial guidance. Â
"We... More
